Mass spectrometry to detect Alzheimer's disease
pftplus |
The MASSPROT platform is contributing to the characterisation of proteins involved in Alzheimer's disease.
While today only an autopsy can determine with certainty whether a patient is suffering from Alzheimer's disease or another neurodegenerative pathology, scientists at UCLouvain have discovered a way to reliably diagnose the Alzheimer's disease while the patient is still alive.
How?
By using mass spectrometry to analyse the 'post-translational' modifications of the soluble Tau protein, i.e. the modifications that affect any protein produced.
This study was published in Nature Communications.